Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of a New Class of Synthetic Anti-Effectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.
Proprietary new class of anti-infectives against bacteria and viruses
Designed to work against antibiotic-resistant bacteria.
Multiple Phase I and Phase II clinical programs, addressing unmet medical needs
A Universal Mechanism of Action
Recce’s New Class of Synthetic Anti-Infectives have a universal mechanism of action with the ability to overcome hyper-cellular mutation of bacteria and viruses. Recce’s anti-infectives are unique – their potency does not diminish even with repeated use, a common failure associated with existing drugs.
Recce continues to strengthen and expand its product pipeline of therapeutic options for ‘difficult to treat’ bacterial and viral infections – including their mutated forms.
$ 0 .0
Change $0.001 / 3.1%